[Form 3] Nasus Pharma Ltd Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Nasus Pharma Ltd director Ronnie Hershman filed an initial ownership report showing existing equity and derivative holdings in the company. The filing lists options to purchase 63,017 Ordinary Shares at an exercise price of $4.297 per share, fully vested and exercisable until May 6, 2030. It also shows warrants to purchase up to 17,970 Ordinary Shares at $6.53 per share, issued February 13, 2026, and exercisable until the earlier of two years from issuance or 30 trading days after announcement of top-line results from the NS002 Pivotal Study. Indirect holdings include 909,156 Ordinary Shares and the warrants through Hershman Holdings, LLC and 429,307 Ordinary Shares through Phoenix Solutions Ltd., which Hershman may be deemed to beneficially own.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Hershman Ronnie
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share options (right to buy) | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share options (right to buy) — 63,017 shares (Direct);
Warrants — 17,970 shares (Indirect, By Hershman Holdings, LLC);
Ordinary Shares — 909,156 shares (Indirect, By Hershman Holdings, LLC)
Footnotes (1)
- Represents ordinary shares of the Issuer, no par value ("Ordinary Shares") directly held by Hershman Holdings, LLC. Dr. Ronnie Hershman, as the managing member of Hershman Holdings, LLC, may be deemed to beneficially own the Ordinary Shares owned directly by Hershman Holdings, LLC. Represents Ordinary Shares directly held by Phoenix Solutions Ltd. Dr. Ronnie Hershman, as a controlling shareholder of Phoenix Solutions Ltd., may be deemed to beneficially own the Ordinary Shares owned directly by Phoenix Solutions Ltd. The options to purchase 63,017 Ordinary Shares were granted on May 6, 2020, with 25% of the total grant vesting on May 6, 2021, and the remaining 75% vesting in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 63,017 options are vested and exercisable at an exercise price of $4.297 per share, expiring May 6, 2030. The warrants to purchase up to 17,970 Ordinary Shares (the "Warrants") were issued on February 13, 2026. The Warrants have an exercise price of $6.53 per share, were immediately exercisable, and will expire upon the earlier of two years from the date of issuance and 30 trading days following the Issuer's announcement of the top-line results of the Issuer's NS002 Pivotal Study. The Warrants are directly held by Hershman Holdings, LLC. Dr. Ronnie Hershman, as the managing member of Hershman Holdings, LLC, may be deemed to beneficially own the Warrants owned directly by Hershman Holdings, LLC.
FAQ
What does Nasus Pharma (NSRX) director Ronnie Hershman report on this Form 3?
Dr. Ronnie Hershman reports his existing ownership in Nasus Pharma, including Ordinary Shares held through entities he controls, plus vested options and recently issued warrants. This is an initial disclosure of holdings, not a report of new share purchases or sales.
What are the key terms of the Nasus Pharma (NSRX) warrants reported by Ronnie Hershman?
The warrants allow the purchase of up to 17,970 Ordinary Shares at $6.53 per share. They were issued on February 13, 2026, are immediately exercisable, and expire on the earlier of two years from issuance or 30 trading days after NS002 Pivotal Study top-line results.
Are the Nasus Pharma (NSRX) holdings on this Form 3 direct or indirect for Ronnie Hershman?
The options are reported as directly held by Dr. Hershman. The Ordinary Shares and warrants are indirectly held through Hershman Holdings, LLC and Phoenix Solutions Ltd., entities he controls and through which he may be deemed to beneficially own these securities.